natgillin/translations-raw huggingface dataset:
Methaemoglobinaemia may be accentuated in patients already taking medicinal products known to induce the condition, e.g. sulphonamides, acetanilid, aniline dyes, benzocaine, chloroquine, dapsone, metoclopramide, naphthalene, nitrates and nitrites, nitrofurantoin, nitroglycerin, nitroprusside, pamaquine, para-aminosalicylic acid, phenobarbital, phenytoin, primaquine and quinine (see section 4.4).
Methemoglobinemija se lahko poudari pri bolnikih, ki že jemljejo zdravila, za katera je znano, da povzročajo takšno stanje, na primer sulfonamidi, acetanilid, anilinske barve, benzokain, klorokin, dapson, metoklopramid, naftalen, nitrati in nitriti, nitrofurantoin, nitroglicerin, nitroprusid, pamakin, paraaminosalicilna kislina, fenobarbital, fenitoin, primakin in kinin (glejte poglavje 4.4).
In a carcinogenicity study of rats exposed to 2,6-xylidine in utero, postnatally and throughout their lifetime, tumours in the nasal cavity, subcutaneous tumours and liver tumours were observed.
V študiji karcinogenosti pri podganah, izpostavljenih 2,6-ksilidinu in utero po povrženju in skozi celotno življenjsko dobo, so opazili tumorje v nosni votlini, podkožne tumorje in tumorje na jetrih.
Senstend may reduce the possibility of pregnancy, but is not a reliable contraceptive.
Zdravilo Senstend lahko zmanjša možnost zanositve, vendar ni zanesljiv kontraceptiv.
Prilocaine was not genotoxic and the carcinogenic potential of prilocaine has not been studied.
Prilokain ni bil genotoksičen in karcinogeni potencial prilokaina ni bil raziskan.
In carcinogenicity studies of o-toluidine in rats, mice and hamsters, tumours were observed in several organs.
Pri študijah karcinogenosti o-toluidina pri podganah, miših in hrčkih so opazili tumorje v več organih.
The prilocaine metabolite o-toluidine has genotoxic potential in vitro.
Presnovek prilokaina, o-toluidin, ima genotoksičen potencial in vitro.
What you need to know before you use Senstend Do not use Senstend
Kaj morate vedeti, preden boste uporabili zdravilo Senstend
Senstend may also come into contact with other mucous membranes such as your, or your partner's, mouth, nose and throat, causing them to feel slightly numb for a short while.
Zdravilo Senstend lahko pride v stik tudi z drugimi sluznicami, na primer ust, nosu in žrela vas ali vaše partnerke, kar za kratek čas povzroči rahlo omrtvelost.
Vulvovaginal discomfort or burning sensation caused discontinuation of treatment in 0.3% of subjects.
Zaradi neprijetnega ali pekočega občutka v vulvovaginalnem področju je prišlo do prekinitve zdravljenja pri 0,3 % preiskovancev.
Although the systemic availability of prilocaine by cutaneous absorption of Senstend is low, caution should be exercised in patients with anaemia, congenital or acquired methaemoglobinaemia or patients on concomitant therapy known to produce such conditions.
Čeprav je sistemska razpoložljivost prilokaina z dermalno absorpcijo zdravila Senstend nizka, je potrebna previdnost pri bolnikih z anemijo, prirojeno ali pridobljeno methemoglobinemijo in pri bolnikih, ki prejemajo sočasno zdravljenje, za katerega je znano, da povzroča takšna stanja.
What Senstend is and what it is used for What you need to know before you use Senstend How to use Senstend
Kaj je zdravilo Senstend in za kaj ga uporabljamo Kaj morate vedeti, preden boste uporabili zdravilo Senstend Kako uporabljati zdravilo Senstend Možni neželeni učinki
Talk to your doctor or pharmacist before using Senstend - if you, or your sexual partner, have been diagnosed with a genetic disease or other condition affecting your red blood cells (glucose-6-phosphate deficiency, anaemia or methaemoglobinaemia); - if you have a history of medicine sensitivities, especially if you are not certain which medicine causes sensitivity; - if you suffer from severe liver problems.
Pred začetkom uporabe zdravila Senstend se posvetujte z zdravnikom ali farmacevtom: - če so vam ali vaši spolni partnerki postavili diagnozo genetske bolezni ali drugega stanja, ki vpliva na vaše rdeče krvne celice (pomanjkanje glukoza-6-fosfat dehidrogenaze, anemija ali methemoglobinemija); - če imate občutljivost na zdravila v anamnezi, zlasti če niste prepričani, katero zdravilo občutljivost povzroča; - če imate resne težave z jetri.
Patients allergic to paraaminobenzoic acid derivatives (procaine, tetracaine, benzocaine, etc.) have not shown cross sensitivity to lidocaine and/or prilocaine; however, Senstend should be used with caution in patients with a history (or partner with a history) of sensitivities to medicinal products, especially if the aetiologic medicinal product is uncertain.
Pri bolnikih, ki so alergični na derivate paraaminobenzojske kisline (prokain, tetrakain, benzokain itd.), niso zabeležili navzkrižne občutljivosti na lidokain in/ali prilokain; vendar je potrebna previdnost pri uporabi zdravila Senstend pri bolnikih (ali njihovih partnerkah) s preobčutljivostmi na zdravila v anamnezi, zlasti kadar etiologija zdravila ni znana.
In an in vitro study of rats Senstend has shown a reduction in sperm motility when 22.5 mg lidocaine and 7.5 mg prilocaine (i.e. the amount in 1 human dose) was in direct contact with rat sperm.
V študiji in vitro pri podganah je zdravilo Senstend zmanjšalo gibljivost semenčic, kadar je bil odmerek 22,5 mg lidokaina in 7,5 mg prilokaina (tj. količina 1 odmerka pri človeku) v neposrednem stiku s podganjo spermo.
Clinical trials have shown Senstend to increase the intra-vaginal ejaculatory latency time (IELT), increase control over ejaculation and reduce the feelings of distress in patients with premature ejaculation as measured by the Index of Premature Ejaculation (IPE).
V kliničnih preskušanjih so zabeležili, da zdravilo Senstend poveča trajanje intravaginalne ejakulacijske latence (IELT), poveča nadzor nad ejakulacijo ter zmanjša občutek osebne stiske pri bolnikih s prezgodnjo ejakulacijo, kar so izmerili z indeksom prezgodnje ejakulacije (Index of Premature Ejaculation, IPE).
In Senstend-treated subjects, IELT and IPE scores increased at the first measured timepoint.
Pri preiskovancih, ki so prejemali zdravilo Senstend, so se rezultati IELT in IPE povišali pri prvi izmerjeni časovni točki.
85.2% of subjects in the Senstend group achieved a mean IELT of > 1 minute over the course of 3 months of treatment with it, whereas 46.4% of the placebo subjects had a mean IELT of > 1 minute.
85,2 % preiskovancev iz skupine, ki je prejemala zdravilo Senstend, je doseglo sredino IELT > 1 minuto v času 3-mesečnega zdravljenja z zdravilom, medtem ko je sredino IELT > 1 minuto doseglo 46,4 % preiskovancev, ki so prejemali placebo.
The lidocaine metabolite 2,6-xylidine has genotoxic potential in vitro.
Presnovek lidokaina 2,6-ksilidin ima genotoksičen potencial in vitro.
There is no relevant use of Senstend in the paediatric population for the indication of treatment of primary premature ejaculation in adult men.
Ustrezne uporabe zdravila Senstend pri pediatrični populaciji za indikacijo zdravljenja primarne prezgodnje ejakulacije pri odraslih moških ni.
Senstend sprayed onto mucous membranes of the patient or their partner, such as the mouth, nose and throat, or transferred onto female genitalia or anal lining, could be absorbed and temporary local numbness/anaesthesia is likely to result.
Če se zdravilo Senstend razprši v sluznice bolnika ali njegove partnerke, na primer ust, nosu ali žrela, ali prenese na ženska spolovila ali analne dele, se lahko absorbira in povzroči začasno lokalno omrtvelost/anestezijo.
Patients or their partner with glucose-6-phosphate dehydrogenase deficiency or congenital or idiopathic methaemoglobinaemia are more susceptible to medicinal product-induced methaemoglobinaemia (see section 4.5).
Bolniki ali njihove partnerke s pomanjkanjem glukoza-6-fosfat dehidrogenaze ali prirojeno ali idiopatično methemoglobinemijo so dovzetnejši za methemoglobinemijo zaradi uporabe zdravil (glejte poglavje 4.5).
If you use more Senstend than you should
Če ste uporabili večji odmerek zdravila Senstend, kot bi smeli:
Men satisfying the International Society for Sexual Medicine (ISSM) criteria for premature ejaculation (PE) who had a baseline IELT ≤ 1 minutes in at least 2 of the first 3 sexual encounters during screening were eligible to enrol.
V študiji so lahko sodelovali moški, ki so izpolnjevali merila Mednarodnega združenja za spolno medicino (International Society for Sexual Medicine, ISSM) glede prezgodnje ejakulacije (PE) z začetno vrednostjo trajanja intravaginalne ejakulacijske latence (IELT) ≤ 1 minuta pri vsaj 2 od prvih 3 spolnih odnosov med presejanjem.
Plasma levels of these metabolites detected after administration of Senstend in clinical trials were low in both male and female subjects, even after doses of it many times in excess of the clinical dose were applied.
Ravni teh presnovkov v plazmi, zaznanih po nanosu zdravila Senstend v kliničnih preskušanjih, so bile nizke pri moških in tudi ženskih preiskovancih celo pri nanosu odmerkov, veliko večjih od kliničnega.
The effectiveness of Senstend in treating PE was assessed by measuring IELT and the co primary endpoints of ejaculatory control, sexual satisfaction, and distress using the IPE.
Učinkovitost zdravila Senstend pri zdravljenju prezgodnje ejakulacije so ocenili z merjenjem IELT in soprimarnih končnih točk nadzora nad ejakulacijo, zadovoljstva s spolnim odnosom in osebne stiske z uporabo IPE.
Common Hypoaesthesia of male genital, erectile dysfunction, genital burning sensation
Hipestezija moških spolovil, erektilna disfunkcija, pekoč občutek spolovil
Senstend sprayed onto a damaged tympanic membrane may cause ototoxicity of the middle ear.
Če se zdravilo Senstend razprši na poškodovan ušesni bobnič, lahko to povzroči ototoksičnost srednjega ušesa.
• Phenobarbital, phenytoin - used to treat epilepsy
• fenobarbital, fenitoin - uporabljata se za zdravljenje epilepsije;
- if you or your sexual partner are allergic to lidocaine or prilocaine or any of the other ingredients of this medicine (listed in section 6); - if you or your sexual partner have a history of allergy or sensitivity to other local anaesthetics with a similar structure (known as amide-type local anaesthetics).
Ne uporabljajte zdravila Senstend: - če ste vi ali vaša spolna partnerka alergični na lidokain ali prilokain ali katero koli sestavino tega zdravila (navedeno v poglavju 6); - če imate vi ali vaša spolna partnerka alergijo na ali ste občutljivi na druge lokalne anestetike s podobno strukturo (znanimi kot lokalni anestetiki amidnega tipa) v anamnezi.
Uncommon Anorectal discomfort, oral parasthesia
Neprijetni občutek v anorektalnem področju, peroralna parestezija
Uncommon Genital erythema, ejaculation failure, paraesthesia of male genital, penile pain, penis disorder, pruritus genital
Eritem spolovil, odsotnost ejakulacije, parestezija moških spolovil, bolečine v penisu, težave s penisom, srbenje spolovil
Senstend is indicated for the treatment of lifelong premature ejaculation in adult men.
Zdravilo Senstend je indicirano za zdravljenje vseživljenjske prezgodnje ejakulacije pri odraslih moških.
The following side effects have been reported with Senstend in male patients:
Pri uporabi zdravila Senstend so poročali o naslednjih neželenih učinkih pri moških bolnikih:
Due to the risk of partner transfer, patients hoping to achieve conception should either avoid using Senstend, or, if it is essential to achieve penetration, should wash the glans penis as thoroughly as possible 5 minutes after applying the spray but prior to intercourse (see section 4.6).
Zaradi tveganja prenosa na partnerko naj se bolniki, ki želijo spočeti otroka, izogibajo uporabi zdravila Senstend, če je njegova uporaba nujna za dosego penetracije, pa naj si 5 minut po nanosu pršila, vendar pred spolnim odnosom, čim temeljiteje sperejo glavico penisa (glejte poglavje 4.6).
The risk of additional systemic toxicity should be considered when large doses of Senstend are applied to patients already using other local anaesthetics or structurally related medicinal products, e.g. class I anti-arrhythmics such as mexiletine.
Pri nanosu večjih količin zdravila Senstend pri bolnikih, ki že uporabljajo druge lokalne anestetike ali strukturno povezana zdravila, npr. antiaritmike razreda I kot meksiletin, je treba upoštevati tveganje za dodatno sistemsko toksičnost.
• pain or discomfort in and around the penis
• bolečina ali neprijeten občutek v penisu in okrog njega;
Holding the can upright (valve up), apply 1 dose (3 sprays) of Senstend to the entire head of the penis, by covering one third with each spray.
Vsebnik držite navzgor (ventil obrnjen navzgor) in na celotno glavico penisa nanesite 1 odmerek (3 razpršitve) zdravila Senstend, tako da z vsako razpršitvijo prekrijete eno tretjino.
• Para-aminosalicylic acid (PAS) - used to treat tuberculosis
• paraaminosalicilna kislina (PAS) - uporablja se za zdravljenje tuberkuloze.
Adverse drug reactions in male glans-penis-treated subjects System Organ Class
Neželeni učinki zdravila pri moških preiskovancih, ki so prejemali zdravljenje glavice penisa Organski sistem
Patients hoping to achieve conception should either avoid using Senstend, or, if it is essential to achieve penetration, should wash the glans penis as thoroughly as possible prior to intercourse.
Bolniki, ki želijo spočeti otroka, naj se izogibajo uporabi zdravila Senstend, če je njegova uporaba nujna za dosego penetracije, pa naj si pred spolnim odnosom čim temeljiteje sperejo glavico penisa.
Cutaneous spray, solution Colourless to light yellow solution
FARMACEVTSKA OBLIKA dermalno pršilo, raztopina Brezbarvna do svetlo rumena raztopina
The following side effects have been reported with Senstend in female partners:
Pri uporabi zdravila Senstend so poročali o naslednjih neželenih učinkih pri partnerkah:
Senstend is a colourless to light yellow cutaneous spray, solution in an aluminium spray container with metering valve.
Izgled zdravila Senstend in vsebina pakiranja Zdravilo Senstend je brezbarvna do svetlo rumena raztopina za dermalno pršilo v aluminijastem vsebniku s pršilom z odmernim ventilom.
Patients with severe hepatic disease, because of their inability to metabolise local anaesthetics normally, are at greater risk of developing toxic plasma concentrations of lidocaine and prilocaine (see section 4.2).
Pri bolnikih s hudo jetrno boleznijo obstaja večje tveganje za razvoj toksičnih koncentracij lidokaina in prilokaina v plazmi zaradi nezmožnosti normalne presnove lokalnega anestetika (glejte poglavje
Senstend is indicated for the treatment of primary premature ejaculation in adult men.
Zdravilo Senstend je indicirano za zdravljenje primarne prezgodnje ejakulacije pri odraslih moških.
Senstend provides topical anaesthesia to the glans penis.
Zdravilo Senstend zagotavlja lokalno anestezijo glavice penisa.
As Senstend is applied topically to the glans penis the risk of overdose is low.
Ker se zdravilo Senstend nanaša lokalno na glavico penisa, je tveganje za preveliko odmerjanje nizko.
Therefore, patients hoping to achieve conception should either avoid using Senstend, or, if this medicine is essential to achieve penetration, should wash the penis as thoroughly as possible five minutes after Senstend has been applied, but prior to intercourse.
Zato naj se bolniki, ki želijo spočeti otroka, izogibajo uporabi zdravila Senstend, če je uporaba tega zdravila nujna za dosego penetracije, pa naj si pet minut po nanosu zdravila Senstend, vendar pred spolnim odnosom, čim temeljiteje sperejo glavico penisa.
Deterioriation was observed when Senstend was used with polyurethane-based female and male condoms.
Pri uporabi zdravila Senstend z ženskimi ali moškimi kondomi na osnovi poliuretana so opazili poslabšanje.
vulvovaginal pruritus
Ledvična okvara
A higher rate of erectile dysfunction and male genital hypoaesthesia may be experienced when using Senstend with male condoms.
Pri uporabi zdravila Senstend z moškimi kondomi je mogoče pričakovati višjo stopnjo erektilne disfunkcije in hipestezije moškega spolovila.
• abnormal orgasm
• motnje orgazma;
Senstend 150 mg/ml + 50 mg/ml cutaneous spray, solution lidocaine/prilocaine
Senstend 150 mg/50 mg v 1 ml dermalno pršilo, raztopina lidokain/prilokain
Senstend is only indicated for application to the glans penis.
Zdravilo Senstend je indicirano samo za nanos na glavico penisa.
• reduced feeling in and around the penis
• zmanjšano čutenje v penisu in okrog njega;
Before each subsequent dose, briefly shake the spray container and then re-prime the pump by spraying 1 time into the air.
Pred vsakim naslednjim odmerkom na kratko pretresite vsebnik s pršilom in ga aktivirajte tako, da 1-krat razpršite v zrak.
No teratogenic effects were observed in studies of embryonic/foetal development in rats and rabbits receiving doses during organogenesis.
V študijah razvoja zarodka/ploda pri podganah in kuncih, ki so odmerke prejemali med organogenezo, niso opazili nobenih teratogenih učinkov.
- The active substances are lidocaine and prilocaine.
Kaj vsebuje zdravilo Senstend - Učinkovini sta lidokain in prilokain.
Once the can is held upright (valve up), 1 dose of Senstend should be applied to the entire glans penis, by actuating the valve 3 times.
Vsebnik držite navpično (ventil obrnjen navzgor) in s tremi potiski ventila na celotno glavico penisa nanesite 1 odmerek zdravila Senstend.
Senstend 150 mg/ml + 50 mg/ml cutaneous spray, solution
IME ZDRAVILA Senstend 150 mg/50 mg v 1 ml dermalno pršilo, raztopina
Medicinal products subject to medical prescription
DRUGI POGOJI IN ZAHTEVE DOVOLJENJA ZA PROMET Z ZDRAVILOM
How to store Senstend
Shranjevanje zdravila Senstend
Contents of the pack and other information What Senstend contains
Shranjevanje zdravila Senstend Vsebina pakiranja in dodatne informacije
• redness on and around the penis
• srbenje v penisu in okrog njega;
• feeling of burning in and around the penis
• pekoč občutek v penisu in okrog njega.
Common Vulvovaginal burning sensation, hypoaesthesia Uncommon Vulvovaginal discomfort, vaginal pain,
Neprijetni občutek v vulvovaginalnem področju, bolečina v nožnici, srbenje vulvovaginalnega področja
Cutaneous spray, solution 6.5 ml
FARMACEVTSKA OBLIKA IN VSEBINA dermalno pršilo, raztopina 6,5 ml
Nervous system disorders
Motnje orgazma
The recommended dose is 2 inhalations twice a day.
Priporočeni odmerek sta dve inhalaciji dvakrat na dan.
Further information on Bevespi Aerosphere can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/Bevespi-Aerosphere.
Nadaljnje informacije za zdravilo Bevespi Aerosphere so na voljo na spletni strani agencije: ema.europa.eu/medicines/human/EPAR/Bevespi-Aerosphere.
The medicine has also shown some effect on symptoms such as breathlessness although this appears modest.
Zdravilo je pokazalo tudi nekaj vpliva na simptome, kot je zasoplost, a se zdi skromen.
The European Medicines Agency therefore decided that Bevespi Aerosphere's benefits are greater than its risks and it can be authorised for use in the EU.
Evropska agencija za zdravila je zato zaključila, da so koristi zdravila Bevespi Aerosphere večje od z njim povezanih tveganj in da se lahko odobri za uporabo v EU.
In these studies, patients treated with Bevespi Aerosphere for 24 weeks had FEV1 increases of around 135 to 150 ml.
V teh študijah se je pri bolnikih, zdravljenih z zdravilom Bevespi Aerosphere 24 tednov, FEV1 z okoli 135 ml povečal na 150 ml.
The combination has been shown to be effective at improving patients' lung function, with both components contributing to this effect.
Njuna kombinacija se je izkazala za učinkovito pri izboljševanju delovanja pljuč, saj obe prispevata k temu učinku.
Bevespi Aerosphere (glycopyrronium bromide / formoterol) EMA/752588/2018
Bevespi Aerosphere (glikopironijev bromid/formoterol) EMA/752588/2018
What measures are being taken to ensure the safe and effective use of Bevespi Aerosphere?
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Bevespi Aerosphere?
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Bevespi Aerosphere have been included in the summary of product characteristics and the package leaflet.
Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Bevespi Aerosphere upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
Patients who received placebo (a dummy treatment), on the other hand, had increases of up to 8 ml or reductions of up to 20 ml.
Pri bolnikih, ki so prejemali placebo (zdravilo brez učinkovine), se je povečal za največ 8 ml ali zmanjšal za največ 20 ml.
The most common side effects with Bevespi Aerosphere (which may affect up to 1 in 10 people) include headache, nausea (feeling sick), muscle spasms and dizziness.
Najpogostejši neželeni učinki zdravila Bevespi Aerosphere (ki se lahko pojavijo pri največ 1 od 10 bolnikov) vključujejo glavobol, navzejo (siljenje na bruhanje), mišične krče in omotičnost.
Three main studies in over 5,000 patients with COPD have shown that Bevespi Aerosphere is effective at improving patients' FEV1 (the maximum volume of air they can breathe out in one second).
V treh glavnih študijah pri več kot 5 000 bolnikih s KOPB so pokazali, da je zdravilo Bevespi Aerosphere učinkovito pri izboljševanju bolnikovega FEV1 (največja prostornina zraka, ki jo lahko izdihne v eni sekundi).
This means that it blocks muscarinic receptors (targets) in muscle cells in the lungs.
To pomeni, da zavira muskarinske receptorje (prijemališča) v mišičnih celicah v pljučih.
For more information about using Bevespi Aerosphere, see the package leaflet or contact your doctor or pharmacist.
Za več informacij glede uporabe zdravila Bevespi Aerosphere glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
Patients should be shown how to use the inhaler correctly by a doctor or other healthcare professional.
Bolnikom mora zdravnik ali drug zdravstveni delavec pokazati, kako pravilno uporabljati inhalator.
Bevespi Aerosphere (glycopyrronium bromide / formoterol)
Bevespi Aerosphere (glikopironijev bromid/formoterol)
As for all medicines, data on the use of Bevespi Aerosphere are continuously monitored.
Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Bevespi Aerosphere stalno spremljajo.
Side effects reported with Bevespi Aerosphere are carefully evaluated and any necessary action taken to protect patients.
Neželeni učinki, o katerih so poročali pri zdravilu Bevespi Aerosphere, se skrbno ovrednotijo in po potrebi sprejmejo ukrepi za zaščito bolnikov.
Formoterol is a long-acting beta-2 agonist.
Formoterol je dolgodelujoči agonist adrenergičnih receptorjev beta2.
Bevespi Aerosphere is used for maintenance (regular) treatment.
Zdravilo Bevespi Aerosphere se uporablja za vzdrževalno (redno) zdravljenje.
Other information about Bevespi Aerosphere
Druge informacije o zdravilu Bevespi Aerosphere
Side effects are considered mild to moderate in severity and are similar to other COPD medicines.
Neželeni učinki so blagi do zmerni in podobni drugim zdravilom za KOPB.
Finally, the studies showed that Bevespi Aerosphere can lead to modest improvements in symptoms such as breathlessness.
Nazadnje so študije pokazale, da lahko Bevespi Aerosphere privede do skromnega izboljšanja pri simptomih, kot je zasoplost.
Glycopyrronium bromide is a muscarinic receptor antagonist.
Glikopironijev bromid je antagonist muskarinskih receptorjev.
The studies also showed that Bevespi Aerosphere improved FEV1 more than the single components in the medicine.
Študije so pokazale tudi, da je zdravilo Bevespi Aerosphere izboljšalo FEV1 bolj kot posamezne sestavine v zdravilu.
An overview of Bevespi Aerosphere and why it is authorised in the EU
Pregled zdravila Bevespi Aerosphere in zakaj je odobreno v EU
Because these receptors help control the contraction of muscles, when glycopyrronium is inhaled, it causes the muscles of the airways to relax, helping to keep the airways open.
Ker ti receptorji pomagajo pri nadzoru krčenja mišic, se po vdihu glikopironija mišice dihalnih poti sprostijo, kar pomaga ohranjati dihalne poti prehodne.
Bevespi Aerosphere is available as a liquid in a portable inhaler device.
Zdravilo Bevespi Aerosphere je na voljo kot tekočina v prenosnem inhalatorju.